Viyash Scientific Limited (VIYASH) — Announcement

1 Announcement Neutral 📄 PDF

📢 Key Event
Viyash Scientific acquires BioForLife Italia for ₹188 crore to expand European pet care presence

🔮 What's Next
Q2 FY27

💡 Investor Takeaway
This acquisition strengthens Viyash's European footprint and growth potential in the high-demand companion animal health market.

Viyash Scientific announced its acquisition of Italy's BioForLife Italia S.r.l. for approximately ₹188 crore to expand its European companion animal health business, with the deal expected to close in Q2 FY27 and enhance its global pet care growth strategy.

2 Announcement Neutral 📄 PDF

📢 Key Event
Viyash signs binding agreement to acquire 100% of BioForLife Italia

🔄 What Changed
€16.975 million acquisition announced

🔮 What's Next
Initial closing expected within 3 months

💡 Investor Takeaway
The acquisition expands Viyash's presence in Italy's animal health market through a €16.975 million purchase.

Viyash Scientific announced it has signed a binding agreement to acquire 100% of BioForLife Italia s.r.l., an Italian animal health company with approximately €9 million in annual sales, for a total consideration of €16.975 million (€15 million cash at closing plus €1.975 million deferred). The acquisition aims to expand Viyash's presence in Italy's companion animal pharmaceutical market and is subject to regulatory approvals, with closing expected within three months. This strategic move diversifies Viyash's geographic footprint and product portfolio in the growing animal health sector.

📊 Stock Analysis — VIYASH ✨ Ask AI About This